The role of miR-182 and FOXO genein patients with colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in the world. Every year, more than 2-1 million new patients with this cancer are diagnosed and more than 600,000 people die. In the past decade, it has been established that aberrant changes in microRNA expression play a functional role in the initiation and progression of CRC. The aim of this study is to investigate the role of miR-182 and its effect on the regulation of FOXO proteins, especially in the initiation and progression of tumors in patients with CRC.

In this research, recent articles and reports from the Cancer Genome Atlas (TCGA) database regarding miR-182, as an oncogene that negatively regulates several tumor suppressor genes, including BRCA1, FOXO1, FOXO3, and MITF, were analyzed and checked.

The results show that miR-182 is significantly increased in CRC tissue compared to normal intestinal tissue and causes negative regulation of FOXO1 and FOXO3 genes.

The regulation of FOXO proteins by miR-182 is involved in tumor initiation and progression in CRC patients. How signaling networks integrate with FOXO transcription factors to modulate developmental, metabolic, and tumor suppressor functions in normal tissues and colorectal cancer provides a new perspective on tumorigenesis and metastasis.